We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.15%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$346M
AUM Growth
+$170M
Cap. Flow
+$163M
Cap. Flow %
46.98%
Top 10 Hldgs %
43.57%
Holding
90
New
39
Increased
14
Reduced
5
Closed
27

Top Buys

1
ACOR
Acorda Therapeutics
ACOR
+$8.81M
2
EW icon
Edwards Lifesciences
EW
+$8.72M
3
BIIB icon
Biogen
BIIB
+$7.91M
4
BLUE
bluebird bio
BLUE
+$7.43M
5
CNMD icon
CONMED
CNMD
+$7.41M

Top Sells

1
CELG
Celgene Corp
CELG
+$6.74M
2
PACB icon
Pacific Biosciences
PACB
+$5.95M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.68M
4
SAGE
Sage Therapeutics
SAGE
+$5.34M
5
IHF icon
iShares US Healthcare Providers ETF
IHF
+$4.82M

Sector Composition

1 Healthcare 56.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHDX
26
DELISTED
Genomic Health, Inc.
GHDX
$5.18M 1.5%
+200,000
New +$5.31M
ICPT
27
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$4.99M 1.44%
+35,000
New +$5.1M
ELGX
28
DELISTED
Endologix Inc
ELGX
$4.98M 1.44%
+40,000
New +$4.6M
BCRX icon
29
BioCryst Pharmaceuticals
BCRX
$2.36B
$4.83M 1.39%
+1,700,000
New +$5.28M
ITCI
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.66M 1.35%
+120,000
New +$4.31M
SAGE
31
CALL
DELISTED
Sage Therapeutics
SAGE
$4.52M 1.31%
+150,000
New +$5M
WMGI
32
DELISTED
Wright Medical Group Inc
WMGI
$4.34M 1.25%
250,000
+125,000
+100% +$2.29M
TSRO
33
CALL
DELISTED
TESARO, Inc.
TSRO
$4.2M 1.21%
+50,000
New +$2.23M
TSRO
34
DELISTED
TESARO, Inc.
TSRO
$4.2M 1.21%
+50,000
New +$2.23M
HZNP
35
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.12M 1.19%
250,000
-175,000
-41% -$2.83M
PCRX icon
36
Pacira BioSciences
PCRX
$1.01B
$4.05M 1.17%
+120,000
New +$5.9M
SRPT icon
37
Sarepta Therapeutics
SRPT
$1.82B
$3.81M 1.1%
+200,000
New +$3.7M
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
$3.76M 1.09%
+350,000
New +$3.73M
HZNP
39
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.29M 0.95%
+200,000
New +$3.24M
RPTP
40
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$3.22M 0.93%
+600,000
New +$3.08M
NSTG
41
DELISTED
NanoString Technologies, Inc.
NSTG
$3.15M 0.91%
250,000
+25,000
+11% +$363K
CELG
42
DELISTED
Celgene Corp
CELG
$2.47M 0.71%
25,000
-65,202
-72% -$6.74M
IMMU
43
DELISTED
Immunomedics Inc
IMMU
$2.32M 0.67%
+1,000,000
New +$3.34M
ENTL
44
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$2.19M 0.63%
120,000
+10,000
+9% +$172K
SRPT icon
45
CALL
Sarepta Therapeutics
SRPT
$1.82B
$1.91M 0.55%
+100,000
New +$1.85M
ICPT
46
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.81M 0.52%
+12,700
New +$1.85M
RIGL icon
47
Rigel Pharmaceuticals
RIGL
$750M
$1.78M 0.52%
+80,000
New +$1.99M
VCYT icon
48
Veracyte
VCYT
$4.72B
$1.72M 0.5%
341,708
– –
LAB icon
49
Standard BioTools
LAB
$350M
$1.35M 0.39%
+150,000
New +$1.41M
ARCT icon
50
Arcturus Therapeutics
ARCT
$172M
$1.35M 0.39%
42,857
– –
1
2
3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Ghost Tree Capital held 90 positions worth $346M, up 96% from $177M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Ghost Tree Capital deployed $163M of net new capital in Q2 2016, opening 39 new positions and adding to 14 existing holdings. Its largest new stake was Acorda Therapeutics: 2,708 shares worth $8.29M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 62% a quarter earlier.

On the sell side, the largest reduction was Celgene Corp, an estimated $6.74M trimmed.

  • Ghost Tree Capital's largest Q2 2016 buy was Acorda Therapeutics: 2,708 shares worth $8.29M.
  • Ghost Tree Capital added most to Alexion Pharmaceuticals in Q2 2016, an estimated $7.09M increase.
  • Ghost Tree Capital's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $6.74M.
  • Ghost Tree Capital fully exited Pacific Biosciences in Q2 2016, selling an estimated $5.95M.
  • Ghost Tree Capital's ten largest holdings make up 44% of its $346M portfolio in Q2 2016.
  • Ghost Tree Capital opened 39 new positions and closed 27 in Q2 2016.
  • Ghost Tree Capital's portfolio value rose 96% quarter-over-quarter to $346M.

Based on Ghost Tree Capital's 13F filing for Q2 2016, filed 12 Aug 2016.